A high incidental rise in cardiac troponin I carries a higher mortality risk in older patients than in those with a diagnosed acute coronary syndrome SIR-Cardiac troponins are highly sensitive and specific biomarkers for myocardial injury [1] . Furthermore, in the context of an acute coronary syndrome (ACS), baseline elevations of troponin have prognostic significance, with a higher risk of death or recurrent infarction early after presentation in patients with a raised troponin [2] . Although troponin is a well-established prognostic marker among patients presenting with unstable coronary syndromes, incidental troponin rises are often encountered in clinical practice where neither an ACS nor another disease associated with an increase in troponin level [3] had been considered.
SIR-Cardiac troponins are highly sensitive and specific biomarkers for myocardial injury [1] . Furthermore, in the context of an acute coronary syndrome (ACS), baseline elevations of troponin have prognostic significance, with a higher risk of death or recurrent infarction early after presentation in patients with a raised troponin [2] . Although troponin is a well-established prognostic marker among patients presenting with unstable coronary syndromes, incidental troponin rises are often encountered in clinical practice where neither an ACS nor another disease associated with an increase in troponin level [3] had been considered.
In older populations, the presentation of an ACS is often non-specific (e.g. falling, confusion) and thus greater reliance is placed upon the troponin result by clinicians for diagnosis. These troponin elevations may not however signify thrombotic ischaemia, and the high sensitivity but low specificity of the test among patients with a low pre-test probability of disease [4] thus confers prognostic uncertainty in this group. This may divert attention from the true underlying clinical problem, leading to unnecessary further cardiac evaluation.
We have previously reported that older people with no apparent cause for a troponin rise were found to have higher short-term readmission rates and mortality compared with those with an ACS or disease known to be associated with a troponin rise [5] . As an incidental rise in troponin appears to be more prevalent in older people [6] , we sought to examine longer-term case fatality of an incidental rise in troponin I in older patients.
Methods

Study population
Two hundred and thirty-seven patients with a troponin I level ≥ 0.04 µg/l measured at least 8 h after the onset of symptoms were recruited from all medical admitting services within a university hospital in the UK from January to May 2004. Our recruitment strategy and the methodology have been reported previously [5] . In brief, we prospectively recruited all patients aged 65 years and over with admission troponin I level ≥ 0.04 µg/l at least 8 h after onset of ischaemic symptoms according to the local reference laboratory values (Beckman Coulter assay, Access Immunoassay System, Beckman Coulter Inc., Fullerton, CA, USA). We took a second recording of troponin I 12 h after admission if in non-specific presentations. The study was approved by the Norfolk Research Ethics Committee.
Categorisation of patients
Patients were prospectively recruited and placed by us into one of three categories based on history, examination, diagnosis made during the ward round by the admitting senior physician and investigation results, including routine admission blood tests and electrocardiograms (ECGs) and chest radiographs.
(1) Definite cardiac cause for troponin rise-ST elevation myocardial infarction (STEMI) based on history of ischaemic symptoms and ECG evidence of ST elevation or other ACS (non-STEMI) based on the presence of ischaemic symptoms and/or ECG evidence of new ischaemic changes (ST depression, T wave inversion or both, or left bundle branch block). (2) Definite non-cardiac cause for troponin rise-pulmonary embolism, arrhythmias, myocarditis, pericarditis, chest trauma, severe congestive cardiac failure, septic shock, chronic renal failure. These patients were excluded in analyses due to the non-cardiac aetiology of their raised troponin. (3) Non-ACS and with no known, identifiable cause for a positive troponin; i.e. incidental finding.
Follow-up data collection
Patients were followed up for all-cause mortality for up to 3 years using the hospital's electronic Patient Administration System. This system records the movement of patients within and between hospitals, and also reports whether an individual is alive or dead at any given time through a system whereby local general practitioners report deaths that occur in the community. The approach is recognised as a pragmatic follow-up method [7] .
Statistical analysis
Data were analysed using SPSS for Windows Version 14.0 (SPSS Inc., Chicago, IL, USA). A threshold of troponin ≥ 0.10 µg/l was used to categorise the magnitude of troponin rise. The choice of cut-off level for a significant level of troponin varies between previously published trials, though a cut-off level between 0.1 and 0.2 µg/l has been proposed to identify patients at higher risk in most trials [1, [8] [9] [10] . The t-test and median tests were implemented for comparisons of normally and non-normally distributed continuous variables, respectively. Continuous variables are described as mean (standard deviation) and skewed variables as median (min, max) values. Associations between categorical variables were assessed using the χ 2 test. Cox-regression models were constructed to examine the mortality risk of patients with an incidental troponin rise compared with those with ACS taking into account confounding effects of age, sex and the level of troponin rise (dichotomised < 0.10 versus ≥0.10 µg/l). Evidence of interaction between explanatory variables was sought. P-values ≤ 0.05 were considered as statistically significant.
Results
Baseline clinical characteristics
Of 237 patients with raised troponin, 146 patients were included after exclusion of 89 patients with a recognised non-ACS cause for their raised troponin and 2 patients with incomplete follow-up information. In total there were 78 (53%) men and 68 (46%) women. Mean age at admission was 81 (standard deviation 8.0) years. Seventy-two deaths occurred during 253 person-years of follow-up (maximum follow-up = 3 years). The numbers of deaths during the follow-up period were 44 for those with an ACS and 28 for those with an incidental rise in troponin. Table 1 summarises the characteristics of each patient category when first admitted to the hospital such as clinical symptoms and diagnoses made by the admitting team. Patients with an incidental rise in troponin were less likely to have presented with chest pain and new ECG changes compared with an ACS.
When comparing the characteristics of patients with an ACS and those with an incidental troponin rise, patients who had an incidental rise in troponin were older 83.7(7.1) years compared with 79.3(7.9) in those with ACS (P = 0.001) and had lower median troponin levels: 0.08 µg/l (min, max 0.04, 1.99) compared with 0.30 (0.04, 100) in those with ACS (P < 0.0001).
Three-year case fatality ACS patients had a median survival of 619 days (1, 1,165) while patients who had an incidental rise in troponin had a median survival of 477 days (1, 1,194) . When examining the prognosis of patients with an incidental troponin rise compared with those with ACS, an interaction was found between the patient category and troponin (P = 0.047). Two separate models for troponin were hence created (troponin ≥ 0.10 and one for troponin < 0.10). Table 2 shows age and sex-adjusted analyses examining prognosis. Patients with an incidental troponin rise ≥ 0.1 had a worse prognosis than those with ACS with the same level of troponin rise. For patients with a troponin < 0.10, patients with an incidental troponin rise had a similar prognosis compared with those with ACS.
Discussion
Our findings suggest that in acutely hospitalised patients aged 65 years and over with an incidental elevation in cardiac troponin I above 0.10, risk of all-cause mortality at up to 3 years is greater than in those who have suffered a confirmed ACS. In those with lower levels of troponin rise, the prognosis with those of an incidental elevation in cardiac troponin I is no better than in those who have suffered an ACS. The estimation of pre-test probability of coronary disease in the prognostic assessment of a raised troponin can be difficult in older patients. First, multiple co-morbidities and social circumstances [11] may affect prognosis in older patients. Secondly, older people may not be as readily diagnosed with an acute coronary condition as advancing age has been associated with atypical presentations [12] , higher pain thresholds and a higher prevalence of painless myocardial infarction [13] . Larger numbers of patients with cognitive disturbance, either as chronic dementia or an acute delirium, compound the challenge of assessing pre-test probability of coronary disease in this age group. Evidence exists demonstrating that invasive cardiac treatments are associated with greater absolute improvements in older, higher-risk patients [14] . Hence, understanding which patients with raised troponin benefit from early intensive cardiac treatment is of importance as the mean age of ACS patients grows steadily yet outcomes in older patients with ACS remain poor [15] . We show here that patients with a high incidental troponin rise are at even higher risk than those with a confirmed ACS. Whether early intensive cardiac treatment improves the outcome of such older patients with a high incidental elevation in cardiac troponin I is not known.
Our study was limited by the lack of a record of preexisting coronary artery disease and of secondary prevention treatment in patients with incidental rises in troponin, while control of potential confounding prognostic variables was limited. We excluded those with a non-ACS but with a recognised cause for a raised troponin in prospective comparative analyses to ensure co-morbidity of patients would not influence outcomes. We aspire to use larger datasets including those with routinely collected, validated clinical data to explore wider factors that influence prognosis. The use of hospital electronic data records for follow-up meant although we have almost 100% complete follow-up data we were unable to examine cause-specific mortality.
In conclusion, our data suggest that an incidental finding of a positive cardiac troponin I above 0.1, in acutely hospitalised patients aged 65 years or over, carries a higher long-term mortality risk than that of a patient admitted due to ACS. This group represents a significant and increasing proportion of older acutely admitted patients.
Key points
• Incidental finding of a positive cardiac troponin I above 0.1 carries risk.
• Lower levels of troponin rise still pose risk.
• Pre-test probability of coronary disease in the prognostic assessment of a raised troponin can be difficult in older patients.
Genetic evidence that vascular dementia is related to Alzheimer's disease: genetic association between tau polymorphism and vascular dementia in the Chinese population SIR-Vascular dementia (VaD) is widely considered to be the second leading cause of dementia after Alzheimer's disease (AD) [1] . It develops when there is impaired blood flow, which would deprive cells of food and oxygen, in some parts of the brain [2] . MAPT (microtubule-associated protein tau) is the gene encoding tau protein. Accumulation of tau protein in the form of neurofibrillary tangles is one of the major characteristics of AD [3] [4] [5] . Therefore, MAPT has long been suspected of being related to AD, but to date there has been no authentic evidence linking MAPT to the disease [6, 7] . To investigate whether MAPT is associated with late-onset AD (LOAD, which is the majority type of AD) in Chinese population and whether it is associated with other types of dementia, we implemented two casecontrol studies, one of 144 LOAD patients, another of 218 VaD patients, and these two studies shared 476 healthy controls. Two single-nucleotide polymorphisms (SNPs) were chosen on MAPT: rs1467967 and rs2471738, both of which have been studied in LOAD before as members of H1c haplotype (see the Supplementary data available in Age and Ageing online).
Methods
VaD patients were diagnosed by at least two clinicians based on the CMAAN (Chinese Medical Association Academy of Neurology) criterion, which integrated the DSM-IV criterion with neuroimaging methods, and thus their disease situations were confirmed by MRI (magnetic resonance imaging) test. LOAD patients were diagnosed according to criteria of DSM-IV and NINCDS-ADRDA. All healthy controls met the Mini-Mental State Examination cutoff of >25 and were without severe psychological disorders, physical disabilities, cancer or communicable diseases. Both groups of patients and controls were all from Shanghai, China. Each participant of this study was given a standard informed consent in the protocol, which was reviewed and approved by the Shanghai Ethical Committee of Human Genetic Resources.
We assessed deviations from Hardy-Weinberg equilibrium (HWE) and compared the differences of allele and genotype frequencies between case group and control group using SHEsis [8] . All genotype groups for the two SNPs were in HWE, except for rs1467967 in the VaD case group. Rs1467967, of which Fisher's P = 0.013734, was assessed for its association with VaD and adjusted for the sex parameter using logistic regression.
We built and tested three models on R-software. In these models, homozygotes for the risk allele (1/1) were coded as 2, heterozygotes (1/0) were coded as 1, and homozygotes for the non-risk allele (0/0) were coded as 0 in the additive model. The dominant model was defined as 1/1 + 1/0 versus 0/0 and the recessive model was as 1/1 versus 1/0 + 0/0. In addition, we calculated the statistical power of the study by using Genetic Power Calculator [9] , which showed the statistical power of this study on detecting an association with VaD or LOAD for rs1467967 and rs2471738.
